Overview
Farid Zerimech practices in Lille, France. Mr. Zerimech is rated as an Advanced expert by MediFind in the treatment of Alpha-1 Antitrypsin Deficiency (AATD). His top areas of expertise are Asthma, Subcutaneous Emphysema, Alpha-1 Antitrypsin Deficiency (AATD), and Pneumonia.
His clinical research consists of co-authoring 58 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Alpha-1 Antitrypsin Deficiency (AATD).
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Alpha-1 Antitrypsin Deficiency (AATD)Mr. Zerimech isAdvanced. Learn about Alpha-1 Antitrypsin Deficiency (AATD).
- AsthmaMr. Zerimech isAdvanced. Learn about Asthma.
- EmphysemaMr. Zerimech isAdvanced. Learn about Emphysema.
- PneumoniaMr. Zerimech isAdvanced. Learn about Pneumonia.
- Subcutaneous EmphysemaMr. Zerimech isAdvanced. Learn about Subcutaneous Emphysema.
- Experienced
- BronchiectasisMr. Zerimech isExperienced. Learn about Bronchiectasis.
- Chronic Obstructive Pulmonary Disease (COPD)
- Gastroesophageal Reflux Disease (GERD)Mr. Zerimech isExperienced. Learn about Gastroesophageal Reflux Disease (GERD).
- Mucopolysaccharidoses (MPS)Mr. Zerimech isExperienced. Learn about Mucopolysaccharidoses (MPS).
- Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome)
- Mucopolysaccharidosis Type 3 (MPS III, Sanfilippo Syndrome)